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Abstract
Background: Cardiovascular disease (CVD) is the single greatest contributor to the gap in life expectancy between
Indigenous and non-Indigenous Australians. Our objective is to determine if holistic CVD risk assessment,
introduced as part of the new Aboriginal and Torres Strait Islander Adult Health Check (AHC), results in better
identification of elevated CVD risk, improved delivery of preventive care for CVD and improvements in the CVD risk
profile for Aboriginal adults in a remote community.
Methods: Interrupted time series study over six years in a remote primary health care (PHC) service involving
Aboriginal adults identified with elevated CVD risk (N = 64). Several process and outcome measures were audited
at 6 monthly intervals for three years prior to the AHC (the intervention) and three years following: (i) the
proportion of guideline scheduled CVD preventive care services delivered, (ii) mean CVD medications prescribed
and dispensed, (iii) mean PHC consultations, (iv) changes in participants’ CVD risk factors and estimated absolute
CVD risk and (v) mean number of CVD events and iatrogenic events.
Results: Twenty-five percent of AHC participants were identified as having elevated CVD risk. Of these, 84% had
not been previously identified during routine care. Following the intervention, there were significant improvements
in the recorded delivery of preventive care services for CVD (30% to 53%), and prescription of CVD related
medications (28% to 89%) (P < 0.001). Amongst participants there was a 20% relative reduction in estimated
absolute CVD risk (P = 0.004) following the intervention. However, there were no significant changes in the mean
number of PHC consultations or mean number of CVD events or iatrogenic events.
Conclusions: Holistic CVD risk assessment during an AHC can lead to better and earlier identification of elevated
CVD risk, improvement in the recorded delivery of preventive care services for CVD, intensification of treatment for
CVD, and improvements in participants’ CVD risk profile. Further research is required on strategies to reorient and
restructure PHC services to the care of chronic illness for Aboriginal peoples in remote areas for there to be
substantial progress in decreasing excess CVD related mortality.
Background
Cardiovascular disease (CVD) is the leading cause of
excess mortality and the greatest single contributor to
the burden of disease for Aboriginal and Torres Strait
Islander Australians [1,2]. Between 25-54 years of age,
CVD deaths for Indigenous Australians occur at 9 to 12
times the rate for non-Indigenous Australians [2].
The Aboriginal and Torres Strait Islander Adult Health
Check (AHC) was launched by Australia’s federal
Government in 2004. The objective of the AHC is “to
encourage early detection, diagnosis and intervention for
common and treatable conditions that cause considerable
morbidity and early mortality” [3]. The AHC comprises a
pre-determined suite of preventive clinical services
including the holistic assessment of CVD risk [3].
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(GPs) are rewarded with a fee for service. Applicable
annually between 15 to 54 years of age, the AHC is a key
component of the strategy to ‘close-the-gap’ in life expec-
tancy between Australia’s Indigenous peoples and the
general population [4,5]. CVD risk assessment within the
AHC has the potential to improve the early detection
and preventive care for CVD, particularly in remote
areas, where CVD contributes disproportionately to the
disease burden [1].
Our objective was to determine if CVD risk assess-
ment during an AHC results in (i) better identification
of elevated CVD risk, (ii) improved delivery of preven-
tive services for CVD and (iii) improvement in the CVD
risk profile for Aboriginal adults in a remote Australian
Aboriginal primary health care service.
Methods
Setting and Participants
The study setting was a large Arnhem Land community
in Australia’s Northern Territory (NT). Analysis of a
clinic register of 440 non-perinatal deaths in this com-
munity over 25 years (1984-2008) showed a mean age at
death of 48 years with 25% of all deaths attributed to
CVD. For deaths occurring between the ages of 15 to 54
(N = 216), 33% were attributed to CVD (unpublished
data). The study setting is also typical of many primary
health care (PHC) services in remote Aboriginal com-
munities in Australia. The service: (i) is understaffed
relative to identified needs [6], (ii) has a high turnover
of non-Aboriginal health staff and (iii) has a predomi-
nant focus on acute care [7,8].
Between March and September 2005, the PHC team
consisting of a GP, remote area nurses (RANs) and
Aboriginal health workers (AHWs) conducted an out-
reach program of AHCs at 16 homelands, township resi-
dences, workplaces and public spaces (outside the
community store and community council buildings).
Prior to 2005, no AHCs had previously been undertaken
and holistic CVD risk assessment was not part of rou-
tine PHC. Participation in the AHC program was on a
voluntary basis. Information sheets were supplied and
written informed consent was obtained from partici-
pants. In our study, the AHC constitutes a complex
health service intervention comprising: (i) identification
of patients with elevated CVD risk, (ii) chronic disease
care planning - a patient centred consultation where
patient education and brief interventions are delivered
and treatment goals are negotiated with patients and
(iii) follow-up of patients for chronic disease monitoring
and further care planning.
During the AHC, CVD risk was assessed using the
New Zealand Guidelines Group (NZGG) handheld chart
based on review of the participant’s medical records,
AHC findings, adjustments for isolated extreme risk fac-
tors and ethnicity (increased by one risk category - 5%)
[9]. Elevated CVD risk was defined as a NZGG chart
risk of ≥10-15% chance of a CVD event over the next
five years - the threshold where pharmacotherapy may
be indicated (number needed to treat for 5 years to pre-
vent one CVD event = 27) [9,10]. AHC participants
with chronic disease diagnoses were offered follow-up
care and care-planning through the PHC service consist-
ing of a multidisciplinary team of GPs (N = 2.0), RANs
(N = 10), AHWs (N = 3).
Clinical Measures
Standardised clinical review
The same questionnaire, equipment and investigations
for CVD risk assessment were used during the AHC
and at a review date, on average, just over a year follow-
ing participation in the AHC. Via an interviewer-
administered questionnaire, we collected self-reported
data on smoking status by asking: “Do you smoke
tobacco?” (yes/no) [11]. Quantification of cigarettes
smoked per day was undertaken using a four-point
visual scale of increasing increments (5,10,15, 20 or
more cigarettes per day) of the most commonly con-
sumed tobacco product. Participants’ weight was
recorded on digital scales to the nearest 100 g, height to
the nearest centimetre using a mounted stadiometer,
and waist measured to the nearest millimetre with an
inelastic tape using standard techniques [12]. Partici-
pants wore light clothing and had bare feet. Body Mass
Index (BMI) was derived by dividing weight in kilograms
b yt h es q u a r eo ft h ep e r s o n ’s height in metres. Three
blood pressure readings at one minute intervals were
obtained on seated participants with an automated
sphygmomanometer (Welch-Allyn: Spot Vital Signs
420TB-E1), using the correct cuff size for the upper arm
circumference. The average of the second and third
readings was calculated and hypertension defined as sys-
tolic blood pressure ≥ 140 mmHg and/or diastolic blood
pressure ≥ 90 mmHg. Non-fasting blood samples were
obtained. High density lipoprotein (HDL), total to HDL
cholesterol ratio (lipid ratio) (colorimetric method) and
blood glucose (hexokinase method) were measured on a
Roche Cobas Integra 800 analyser. Type two diabetes
was assessed by review of patient medical records or an
indicative blood glucose level, confirmed by a subse-
quent oral glucose tolerance test [13].
Estimation of absolute CVD risk
While clinical decision making is based upon the use of
handheld charts to identify patients with elevated CVD
risk [9,14], these charts do not provide a precise estima-
tion of CVD risk. To determine if there were any
changes in the cohort’s mean absolute CVD risk follow-
ing the AHC, estimation of absolute CVD risk was
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dardised clinical assessments (N = 58). We used the Fra-
mingham equations for coronary heart disease risk over
five and ten years [15]. Although these equations have
been demonstrated to underestimate absolute risk in
one remote Aboriginal population [16], the purpose of
this calculation was to identify ‘relative’ changes in the
cohort’s CVD risk subsequent to participation in the
AHC (the intervention). A further issue with the equa-
tions is that they can only be used from the age of 30
[15]. Of the 58 participants completing both standar-
dised clinical assessments, 11/58 (19%) were aged less
than 30 years on the day of the AHC. For the purposes
of absolute CVD risk calculation only, their ages were
adjusted upwards so that they were assessed as if they
were aged 30 on the day of the AHC. The same adjust-
ment was applied to their age for the calculation of
absolute risk when they completed the post-AHC
review. To assess relative changes in the cohort’sm e a n
absolute CVD risk, three calculations were performed:
(i) on the day of AHC participation (baseline risk),
(ii) on the day of post-AHC review (on average,
1.2 years after the AHC), assuming no change in clinical
parameters apart from age (expected post-AHC CVD
risk) and (iii) on the day of post-AHC review using new
clinical findings from the repeated standardised assess-
ment (observed post-AHC CVD risk). A paired two-
tailed t-test was then used to determine if the difference
between the expected and observed measures of the
cohort’s mean absolute CVD risk at follow-up was sta-
tistically significant.
Medical record auditing procedure
Inclusion criteria for the interrupted time-series (ITS)
study were: (i) residence in the community for three
years prior to the date of participation in the AHC and
for three years following AHC participation (6 years in
total), (ii) elevated CVD risk, (iii) participation in the
AHC program (the intervention) and (iv) consent to the
study.
Participants’ medical records were audited for
recorded delivery of NT Preventable Chronic Disease
Strategy (PCDS) scheduled services for ischaemic heart
disease and hyperlipidaemia (Table 1) [17], CVD related
medication prescription, medication dispensing, PHC
consultations, CVD events (myocardial infarction,
stroke/transient ischaemic attack, coronary artery angio-
plasty/stenting) and iatrogenic events (medications
errors, drug side effects, patient complaints).
These outcomes were audited at six-monthly intervals
for three years prior to the date of participation in the
AHC and for three years following the date of participa-
tion in the AHC. Thus, a total of 12 six month intervals
covering six years of PHC for each participant were
audited. Within each six-month interval, each scheduled
NT PCDS CVD preventive service (N = 20) was coded
as delivered (1) or not (0). Services scheduled annually,
if delivered, were coded as delivered both in the interval
in which they occurred and the following six month
interval. The proportion of the 20 NT PCDS scheduled
CVD secondary prevention services delivered in each
time interval was generated by summing services and
dividing by 20. A sub-measure of six services with the
strongest evidence for effectiveness (counselling for
smoking cessation, measurement of blood pressure,
lipids, blood glucose, annual influenza vaccination [18],
and chronic disease care planning [19]) was also gener-
ated by summing these services and dividing by 6.
A paper-based audit tool and audit protocol were
designed by an expert panel and pre-piloted on a random
sample of eight charts [20]. Participants’ charts were
audited by a senior GP (CPB) and a random sample of
twenty charts (31%) was re-audited by CPB to evaluate
intra-rater reliability. Reliability items (N = 12) audited
comprised a range of (i) administrative data (N = 2)
(AHC participation date, date of birth), (ii) categorical
variables (N = 6) (recorded delivery of smoking brief
intervention, blood pressure measurement, blood lipids,
GP consultation, care planning, aspirin prescription), and
(iii) numerical variables (N = 4) (systolic blood pressure,
lipid ratio, number of GP consultations, proportion of
prescribed medications dispensed).
Statistical methods
Double data entry was used to minimise errors during
data input. Means and proportions for CVD risk factors
at the time of AHC and Pearson’s chi square and two
tailed independent samples t-tests for difference based on
gender were performed. For participants who completed
Table 1 NT PCDS recommended clinical service items for
ischaemic heart disease and hyperlipidaemia
CVD secondary prevention services scheduled to be delivered once
every 6 months
Consultations With RAN or AHW, MO
Brief
Interventions
Smoking, Nutrition, Alcohol, Physical activity, Emotional
wellbeing
Clinical/lab
services
Weight, Waist, Blood pressure, Lipids measurement
CVD secondary prevention services scheduled to be delivered once
every 12 months
Consultation With Physician
Interventions Influenza vaccination, Care planning
Clinical/lab
services
ECG, ACR, FBE, LFT, EUC, BGL
Notes: NT PCDS = Northern Territory Preventable Chronic Disease Strategy,
CVD = cardiovascular disease, RAN = remote area nurse, AHW = Aboriginal
health worker, MO = medical officer, ECG = electrocardiograph, ACR = urinary
albumin creatinine ratio, FBE = full blood examination, LFT = liver function
tests, EUC = electrolytes, urea and creatinine, BGL = blood glucose level.
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CVD risk factors were tested using a paired two tailed t-
test or McNemar’s test. For the medical record audit
variables, Cohen’s Kappa statistic for dichotomous out-
comes and quadratic weighted kappa statistic for ordinal
outcomes were calculated to evaluate intra-rater reliabil-
ity. Our criteria for satisfactory intra-rater reliability was
a Kappa statistic of > 0.80 [21]. We calculated that a sam-
ple size of 60 participants would demonstrate a difference
of 1.5 service items to be statistically significant with 80%
power, based on a 2-sample paired t-test with alpha =
0.005 (to allow for multiple testing). Multiple paired two-
tailed t-tests and repeated measures analysis (ANOVA)
were performed to evaluate changes in CVD care out-
comes over time. For the paired two-tailed t-tests used in
the ITS, we used the Holm-Bonferroni adjustment to
control for family wise error among the multiple t-tests
to set an overall 0.05 family wise error rate [22]. All
statistical analysis was undertaken using Stata software
(version 9.2).
Ethics approval
Ethics approval for this study was obtained from Charles
Darwin University (H04053) and the NT Department of
Health and Community Services (04/35). Ethics approval
included independent approval by an Aboriginal ethics
sub-committee and letters of support from the commu-
nity controlled health board and outstation resource
centre.
Results
AHC participants were 301 adults (59% men, N = 177)
aged 15 to 54 years, representing 23.4% of the eligible
population (N = 1284) [23]. The sample age structure
was similar to the most recent census profile (X
2 = 9.63,
P = 0.2) [23]. During the AHC program, 75/301 (25%)
participants were identified as having elevated CVD risk,
with 63/75 (84%) having no previous documentation of
elevated CVD risk. However, 31/63 (49%) of those ‘newly
detected’ had sufficient pre-existing clinical and labora-
tory findings documented for elevated CVD risk to be
identified prior to participation in the AHC. Women
were significantly more likely to have elevated CVD risk
overlooked prior to the AHC (X
2 = 6.5, P = 0.01).
Interrupted time series findings
Eleven participants with elevated CVD risk were
excluded from the ITS study because they had moved
away from the community (Figure 1). The remaining 64
participants with elevated CVD risk were included.
Among this cohort there was one death 18 months
prior to the end of our study. The time series cohort
provided 384 person-years of observation. Among parti-
cipants, there were no significant differences between
men and women in terms of their CVD risk factor pro-
file (Table 2). Following AHC participation, 61/64 (95%)
of the cohort underwent chronic disease care-planning
with a medical officer between 1 and 555 days (mean
177 days) after the AHC. Two participants (3%) had a
pre-existing care plan (that included a CVD related
diagnosis) on the day of participation in the AHC. One
participant did not undergo care planning during the
study period.
Repeat audits were completed between 43 and 79 days
after the initial audit (mean 71 days). Kappa statistics
for all twelve items covered by the repeat audit showed
301  
Adult Health Check 
participants 
75
Identified with  
elevated CVD risk 
64
Eligible for   
interrupted time series study
58
Completed standardised 
post-AHC clinical review 
11
Moved away from the 
community 
1
Declined standardised 
clinical review 
5
Standardised clinical review 
not completed by PHC team 
Figure 1 Flowchart of study participants. Notes: CVD = cardiovascular disease, AHC = adult health check, PHC = primary health care.
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Page 4 of 11a high level of agreement ( range: 0.88 to 1.0, observed
versus expected agreement P < 0.001). Detailed results
are available from the corresponding author.
Prior to the intervention, there were no significant
changes between the first and subsequent time intervals
in the recorded delivery of preventive care services for
CVD (Figure 2 & Table 3). After the intervention and
following Holm-Bonferroni adjustment, recorded deliv-
ery of scheduled CVD preventive care services increased
significantly in all but one of the 6 month periods
Table 2 Time series cohort characteristics at the time of AHC participation (N = 64)
Males Females All P*
Participants N (%) 43 (67%) 21 (33%) 64 -
Mean age in years (SD) 39.6 (8.1) 42.5 (9.1) 40.6 (8.5) 0.21
Current smoker 81% 91% 84% 0.29
Type two diabetes 24% 43% 30% 0.12
Blood pressure ≥ 140/90 mmHg 21% 19% 20% 0.57
Total cholesterol ≥ 4.0 mmol/L 88% 86% 88% 0.53
HDL cholesterol ≤ 1.0 mmol/L 56% 62% 58% 0.43
Lipid ratio ≥ 5.0 (levels of total to HDL cholesterol) 56% 62% 58% 0.43
Mean NZGG 5-year CVD risk category† (SD) 4.5 (0.9) 4.6 (1.0) 4.5 (0.9) 0.66
Notes: AHC = adult health check, N = number, SD = standard deviation, HDL = high density lipoprotein, NZGG = New Zealand Guidelines Group, CVD =
cardiovascular disease.
*Test for difference between men and women. Means were tested using a two-tailed independent samples t-test. Proportions were tested using Pearson’s chi
square test.
† NZGG risk categories: 4 = 10 to 15% over 5 years, 5 = 15 to 20% over 5 years, 6 = 20 to 25% over 5 years, etc.
‡ Calculated using the Framingham equations [15]. The equations have been shown to underestimate risk in one other remote Aboriginal population [16].
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Figure 2 Proportion of scheduled CVD secondary prevention services delivered over time. Notes: CVD = cardiovascular disease, AHC =
adult health check, NTPCDS = Northern Territory Preventable Chronic Disease Strategy. NT PCDS scheduled services comprise all 20 services
detailed in Box 1 of this article. Evidence based CVD preventive services (N = 6): smoking advice, measurement of blood pressure, blood glucose,
lipids, influenza vaccination and chronic disease care planning. Means are calculated for all participants in the time series study (N = 64). The
vertical line mid-graph represents the intervention point: AHC participation.
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Page 5 of 11(repeated measures analysis P < 0.001). Recorded deliv-
ery of the subset of services with the strongest evidence
base demonstrated a similar pattern to the total measure
of NT PCDS CVD related preventive services. However,
for evidence-based preventive care services for CVD, the
improvement in recorded delivery was statistically signif-
icant in all time intervals following the intervention
(table 4).
Prior to the intervention, there was an increase in CVD
medication prescription and dispensing corresponding
with incident CVD events among the cohort members
(Figure 3). However, following Holm-Bonferroni adjust-
ment, the changes between the first and subsequent time
intervals prior to the intervention were not statistically
significant. After the intervention, both the mean number
and proportion of CVD related medication dispensed
increased significantly (repeated measures analysis
P < 0.001). At the start (3 years prior to participation in
the AHC) of the time series 18/64 (28%) of participants
were prescribed CVD related medication, rising to 56/63
(89%) by study end (three years after participation in the
AHC). Anti-platelet drugs, lipid lowering agents, anti-
hypertensives and oral hypoglycaemic agents were more
likely to be prescribed at study end compared to the start
of the study (Table 5). The mean proportion of pre-
scribed CVD related medication dispensed at study end
was 33%.
There were 2921 documented PHC consultations with
medical officers, nurses, Aboriginal health workers and
the visiting physician during the study period. Multiple
two-tailed t-test analysis and repeated measures analysis
did not demonstrate any significant changes in the
mean number of PHC consultations between the first
and subsequent time intervals.
Table 3 Multiple paired t-tests of scheduled CVD services delivered over time compared to baseline (N = 64)
Time period 6 month intervals Mean proportion of CVD services delivered Difference from baseline t-test P*
Baseline 0.30 - - -
2 0.26 -0.04 -0.95 0.35
3 0.24 -0.06 -1.57 0.12
4 0.25 -0.05 -1.21 0.23
5 0.28 -0.02 -0.40 0.68
6 0.26 -0.04 -1.04 0.30
AHC participation (intervention)
7 0.43 0.13 3.49 0.001
8 0.32 0.02 0.52 0.61
9 0.65 0.35 7.84 < 0.001
10 0.54 0.24 5.42 < 0.001
11 0.47 0.17 3.64 < 0.001
12 0.53 0.23 4.84 < 0.001
Notes: CVD = cardiovascular disease, AHC = adult health check, N = number.
*Two-tailed paired t-test for change in mean proportion of CVD services delivered compared with baseline.
Table 4 Multiple paired t-tests of ‘evidence based’ CVD services delivered over time compared to baseline (N = 64)
Time period 6 month intervals Mean proportion of CVD services delivered Difference from baseline t-test P*
Baseline 0.29 - - -
2 0.26 -0.04 -0.81 0.42
3 0.20 -0.09 -2.14 0.03
4 0.23 -0.06 -1.41 0.16
5 0.28 -0.01 -0.37 0.71
6 0.24 -0.05 -1.12 0.26
AHC participation (intervention)
7 0.48 0.19 4.04 < 0.001
8 0.42 0.13 2.55 0.01
9 0.72 0.43 8.48 < 0.001
10 0.62 0.33 6.42 < 0.001
11 0.52 0.23 4.25 < 0.001
12 0.57 0.28 5.18 < 0.001
Notes: CVD = cardiovascular disease, AHC = adult health check, N = number.
*Two-tailed paired t-test for change in mean proportion of CVD services delivered compared with baseline.
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Page 6 of 11There were 8 CVD events prior and 9 (including one
death) following the intervention amongst the time ser-
ies cohort. Six iatrogenic events were documented over
the study period, 2 prior and 4 following the interven-
tion. These included 2 prescribing errors by locum med-
ical officers, a high international normalised ratio level
in one patient prescribed warfarin, one minor vaccina-
tion reaction and 2 errors in pre-packaged medications.
There were no significant trends in mean numbers of
CVD or iatrogenic events between the initial and subse-
quent time intervals.
Cohort CVD risk profile findings
Of the 64 participants in the time-series study (Figure
1), 58 (91%) completed a standardised post-AHC CVD
review between 0.9 and 2.5 years (mean 1.2 years) fol-
lowing the AHC (Table 6). One participant declined the
standardised review when offered. A further five partici-
pants, whilst having contact(s) with the PHC service, did
not receive the standardised review. The six ITS partici-
pants who did not complete the repeat standardised
clinical review were excluded from the cohort CVD risk
profile analysis. Two participants had data missing for
waist circumference or calculation of body mass index.
At the post-AHC review, 6 participants self-reported
that they had ceased smoking and of those who were
smoking on both assessment dates, there was a statisti-
cally significant reduction in the self-reported number
of cigarettes smoked per day. There were significant
changes in terms of reduced waist circumference,
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Figure 3 CVD medication prescribing and recorded dispensing over time. Notes: AHC = adult health check, CVD = cardiovascular disease.
Means are calculated for all participants in the time series study (N = 64). The vertical line mid-graph represents the intervention point: AHC
participation.
Table 5 Medications prescribed at study start (N = 64)
and study end (N = 63)
†
Drug class Baseline N (%) Study end N (%) P*
Anti-platelet 3 (4.7%) 43 (68.3%) < 0.001
Lipid lowering 4 (6.3%) 41 (65.1%) < 0.001
ACEi/ARB 16 (25%) 40 (63.5%) < 0.001
Oral hypoglycaemic 11 (17.2%) 21 (33.3%) 0.04
Beta blocker 3 (4.7%) 8 (12.7%) 0.09
Nitrate 2 (3.1%) 3 (4.8%) 0.49
Thiazide diuretic 0 2 (3.2%) 0.24
Calcium channel blocker 1 (1.6%) 1 (1.6%) 0.75
Notes: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin
receptor blocker.
* Chi Square test for change in proportion of participants prescribed each
class of medication.
† There was one death in the period following the AHC.
Baseline = 3 years prior to date of AHC participation.
Study end = 3 years following date of AHC participation.
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change in mean BMI or the prevalence of diabetes. At
the post-AHC review, the mean estimated absolute
CVD risk over ten years was 20% lower than expected
(P = 0.004), compared with the mean estimated absolute
CVD risk calculated on the presumption of no change
in clinical parameters apart from age between the AHC
and post-AHC review.
Discussion
AHC-based holistic CVD risk assessment resulted in
better identification of elevated CVD risk, improved
delivery of preventive care services for CVD, intensifica-
tion of pharmacotherapy for CVD and improvement in
some intermediate CVD related clinical outcomes in
this remote Aboriginal community.
Consistent with a recent study, we found significant
gaps in screening, recognition of elevated CVD risk and
initiation of risk reduction interventions prior to the
AHC [24]. A strength of the AHC as an intervention, is
the opportunity this presents PHC professionals to close
this evidence-practice gap through the assessment and
management of CVD risk [4]. The high proportion of
those newly identified with elevated CVD risk, particu-
larly those who had this overlooked during routine care,
confirms the merits of holistic appraisal of CVD risk,
rather than focussing on isolated risk factors [14].
A policy implication of our findings is the need to
strengthen implementation of CVD risk assessment for
Indigenous Australians [24]. Reliance upon the AHC as
the only vehicle for CVD risk assessment may be inade-
quate because of the low uptake of the item [25].
Following identification of elevated CVD risk,
recorded delivery of the NT PCDS scheduled preven-
tive care services for CVD improved but also demon-
strated some fluctuation. Reasons for this may include
(i) the high turnover of nursing and medical staff [8],
(ii) competing demands of the acute care workload [8],
(iii) the time delay between the intervention and care-
planning with a medical officer, and/or (iv) the con-
centration of preventive services within annual care
planning consultations. Recorded delivery of preventive
care services for CVD also improved without any
increase in the mean number of PHC consultations.
This finding attests to the potential of the AHC, based
on a patient’s documented risk assessment, to facilitate
a shift from episodic acute care to an increased
emphasis on prevention within a multi-disciplinary
PHC team [4]. However, improvements in preventive
care for CVD in remote communities are likely to
Table 6 CVD risk profile for study participants completing the post-AHC clinical review (N = 58), (figures are mean [SE]
unless otherwise specified)
CVD risk factor AHC Review P*
Current smoker N (%) 48 (83%) 45 (78%) 0.51
Quit smoking N (%) - 6 (13%)
Started or recommenced smoking N (%) - 3 (30%)
Category: cigarettes smoked per day† (N = 41) 3.5 (0.1) 2.6 (0.2) < 0.001
Body mass index kg/m
2 (N = 56) 27.3 (0.9) 27.3 (0.8) 0.81
Waist circumference cm (N = 56) 98.3 (1.8) 96.4 (1.8) 0.04
Systolic blood pressure mmHg 128 (2.6) 124 (3.0) 0.2
Total cholesterol mmol/L 5.5 (0.2) 5.3 (0.2) 0.07
HDL cholesterol mmol/L 1.01 (0.03) 1.11 (0.04) 0.001
Ratio of total to HDL cholesterol 5.7 (0.2) 5.0 (0.2) < 0.001
Type two diabetes N (%) 17 (29%) 17 (29%) 1.0
NZGG 5-year CVD risk category‡ 4.5 (0.1) 4.3 (0.2) 0.11
Expected post-AHC absolute 5-year CVD risk % 4.3 (0.4) 4.6 (0.4) < 0.001
Observed post-AHC absolute 5-year CVD risk % 3.6 (0.4)
Difference in post-AHC absolute 5-year CVD risk % 1.0 (0.4) 0.007§
Expected post-AHC absolute 10-year CVD risk % 9.5 (0.8) 10.2 (0.8) < 0.001
Observed post-AHC absolute 10-year CVD risk % 8.2 (0.7)
Difference in post-AHC absolute 10-year CVD risk % 2.0 (0.7) 0.004§
Notes: CVD = cardiovascular disease, AHC = adult health check, SE = standard error, N = number, HDL = high density lipoprotein, NZGG = New Zealand
Guidelines Group.
* Test for difference between findings at the AHC and at review. Means were tested by a paired two-tailed t-test. Proportions were tested using McNemar’s test.
† Cigarettes per day (cpd) categories: 1 = 5cpd, 2 = 10cpd, 3 = 15 cpd, 4 = 20+ cpd.
‡ NZGG risk categories: 4 = 10 to 15% over 5 years, 5 = 15 to 20% over 5 years, 6 = 20 to 25% over 5 years, etc.
§ Two-tailed t-test for difference between observed absolute CVD risk at post-AHC review and expected (change in age only) absolute CVD risk at post-AHC
review.
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on chronic illness care [19,26]. Research is required
about how best to re-orient health centre systems and
how to structure, recruit, train and retain the requisite
workforce for chronic illness care in remote Aboriginal
communities [8].
The high proportion (98%) of study participants who
underwent care planning and the high proportion (89%)
for whom pharmacotherapy was prescribed by study
end indicates a high level of engagement with preventive
care for CVD by this cohort. However, the increase in
mean documented dispensing of CVD related medica-
tions over time, while also indicative of greater engage-
ment with prevention, may have occurred for reasons
other than the AHC. The gradual introduction of pre-
packaged medications (multi-dose sachets and blister
packs) over the study period may have contributed to
increased medication dispensing. Our findings contrast
with at least one previous study, where a primary health
care system type intervention was not associated with
intensification of medical treatment [27]. Nevertheless,
the low mean proportion of medications dispensed (at
best, 33% at study end), suggests that intervention with
pharmacotherapy was suboptimal. This may explain, in
part, the limited reduction in the cohort’s CVD risk pro-
file (for example blood pressure) despite the significant
increase in medication prescription.
Compared with the only other published study on the
AHC [28], our work contributes new knowledge in sev-
eral important areas. First, our findings document the
population burden of elevated CVD risk. This was not
reported in the former study [28]. Second, we present
prospective data on changes in participants’ CVD risk
profile suggestive of improved outcomes following AHC
participation. Third, we demonstrate the high level of
engagement of Aboriginal participants with preventive
care through chronic disease care planning and assent-
ing to pharmacotherapy. Fourth, we have identified sig-
nificant PHC capacity constraints, in this research
setting, to deliver optimal preventive care services for
CVD through guideline scheduled clinical services and
pharmacotherapy.
This last point is consistent with international experi-
ence - that the addition of new features, such as the AHC,
to an unchanged PHC system focussed on acute care will
have sub-optimal impacts on patients’ chronic disease out-
comes [19]. Transformational rather than incremental
change may be required in remote Aboriginal commu-
nities to shift to an evidence-based chronic care model
[26]. Interventions targeting health providers (such as the
AHC) may need to be accompanied by systematic efforts
to increase patients’ knowledge, skills and confidence to
manage their own conditions [29,30]. In the challenging
setting of remote Aboriginal communities, specific
strategies may be required to: (i) involve family members
in care [19,31], (ii) train and retain a skilled medical and
nursing workforce to provide high quality chronic illness
care [8,19,26] and (iii) improve Aboriginal participation in
the delivery of chronic disease care [8,31,32]. These
remain the ongoing challenges for PHC practitioners, pol-
icy makers, health administrators and health researchers.
The relative reduction in the cohort’s estimated abso-
lute CVD risk attests to the potential of the AHC to
contribute to reductions in the single largest cause of
excess Aboriginal mortality [1,4], even within very chal-
lenging PHC settings. In addition, the reduction in abso-
lute CVD risk may be underestimated in our study
because of the significant reduction in the number of
cigarettes smoked per day in this cohort [33]. The Fra-
mingham equations only include smoking status [14,15].
However, the improvement in participants’ CVD risk
profile must be interpreted with caution. In comparable
settings, such improvements have been difficult to sus-
tain in the long term [34].
A limitation of this study is that we were unable to
report on clinical outcomes throughout the time series.
Our clinical outcomes data, dependent on the PHC ser-
vice’s capacity to deliver preventive clinical services, did
not meet accepted standards for reporting - 80% com-
plete data at each time interval in a time series [21].
Furthermore, the unchanged mean number of CVD
events prior and following the intervention suggest that
the increase in preventive care and gains in intermediate
CVD risk reduction were not sufficient to alter progres-
sion to end-stage disease in the short term. However,
with a small sample size our study was not adequately
powered to detect changes in CVD events. In addition,
it is likely that the follow-up period for this study was
too short to demonstrate such an effect.
Further limitations of this study include: 1) the invol-
vement of the primary researcher/clinician (CPB) in the
implementation of the intervention (the AHC) and the
follow-up of clients identified with elevated CVD risk.
The high level of engagement of this practitioner in the
AHC, CVD assessment and ongoing care is likely to
have been a significant factor in the observed increase
in preventive care. An impact of this magnitude may
not necessarily be expected with large scale implementa-
tion of the AHC. 2) The Framingham risk equations
may underestimate ‘absolute’ CVD risk for Aboriginal
Australians [16]. However, no studies have been pub-
lished on Indigenous Australians applying the adjust-
ments for ethnicity suggested by the New Zealand
Guidelines Group [9,14]. While further work is required
to develop accurate CVD risk assessment for Indigenous
Australians, peak bodies advocate using the adjustments
we have in this study [14]. 3) Potential sources of bias
include the reliance on documentation of preventive
Burgess et al. BMC Health Services Research 2011, 11:24
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We don’t believe the intervention (AHC) affected
recording of preventive services because (i) the AHC is
a discrete medical service for which documentation is
independent of other chronic disease care documents,
(ii) the source and methods of data collection were the
same before and after the intervention and (iii) out-
comes audited were objective( s e r v i c ep r o v i d e do rn o t ,
medication prescribed/dispensed or not). 4) Complex
health service interventions are difficult to evaluate. The
absence of a parallel control group - people identified
with elevated CVD risk for whom intervention was not
offered, may be considered a further limitation. How-
ever, within a population with a high burden of prema-
ture CVD related mortality, withholding intervention
would be unethical and concealment of an intervention
group would be difficult within a single PHC service
with multiple practitioners. The historical controls pro-
vided by an interrupted time series study provide a
robust alternative and our study complies with eligibility
criteria for inclusion in systematic reviews [21].
Conclusions
We conclude that CVD risk assessment during the AHC
can be an effective intervention towards better and ear-
lier detection of elevated CVD risk and population
reductions in CVD risk but significant challenges remain
t oi m p r o v ep r e v e n t i v ec a r ef o rC V D .F u r t h e rw o r ki s
required to understand how to establish effective and
sustainable chronic disease care in remote Aboriginal
PHC settings to decrease excess CVD mortality.
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